SEC For	m 4																	
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).					oursuan	t to Sectio	n 16(a	A) of the Se	curitie	es Exchan	ge Act of 1		HIP	Estima	Numbe ated av per res	erage burden	3235-0287 0.5	
1. Name and Address of Reporting Person [*] Manfredi Mark					2. Issuer Name and Ticker or Trading Symbol <u>Ikena Oncology, Inc.</u> [IKNA]								eck all applica X Director	able)	, 10% Owr			
(Last) (First) (Middle) C/O IKENA ONCOLOGY, INC. 645 SUMMER STREET, SUITE 101					3. Date of Earliest Transaction (Month/Day/Year) 01/03/2023								X Officer (give title Other (specify below) Below) President & CEO				pecity	
(Street) BOSTON	N M	02210	4	l. If Ame	endment, I	Date o	of Original Filed (Month/Day/Year)			Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip)													F (130)					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/E)					ction 2A. Deemed Execution Date,			, 3. Transac Code (la 8)	tion	4. Securi	ff, or Beneficially C ties Acquired (A) or d Of (D) (Instr. 3, 4 and 5) (A) or (D) Price		5. Amoun 5) Securities Beneficia	ount of 6. Ov rities 6 Form ficially (D) o d Following (I) (In rted action(s)		Direct I Indirect I str. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exe Expiration (Month/Day	Date		le and of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)	011(3)			
Stock Option (Right to Buy)	\$2.62	01/03/2023		A		220,000		(1)	01	1/03/2033	Common Stock	220,000	\$0.00	220,00	00	D		

Explanation of Responses:

1. 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

<u>/s/ Mark Manfredi</u>

** Signature of Reporting Person

01/05/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.